Results 131 to 140 of about 12,660 (249)

In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug‐Metabolizing Enzymes

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Bemnifosbuvir is a novel oral guanosine nucleotide prodrug with potent pan‐genotypic inhibitory activity against hepatitis C virus. In vitro studies assessing the inhibition or induction potential of bemnifosbuvir on the CYP450 and UGT1A1 enzymes demonstrated that bemnifosbuvir is a weak inducer and a reversible and time‐dependent inhibitor of
Xiao‐Jian Zhou, Alex Vo, Gaetano Morelli, Maureen Montrond, Shannan Lynch, Keith Pietropaolo, Bruce Belanger, Steven Good, Arantxa Horga, Nancy Agrawal, Janet Hammond   +10 more
wiley   +1 more source

Development and validation of PBPK models for genistein and daidzein for use in a next-generation risk assessment

Frontiers in Pharmacology
IntroductionAll cosmetic ingredients must be evaluated for their safety to consumers. In the absence of in vivo data, systemic concentrations of ingredients can be predicted using Physiologically based Pharmacokinetic (PBPK) models.
A. Najjar, D. Lange, C. Géniès, J. Kuehnl, A. Zifle, C. Jacques, E. Fabian, N. Hewitt, A. Schepky   +8 more
doaj   +1 more source

A minimal PBPK model to accelerate preclinical development of drugs against tuberculosis. [PDF]

Front Pharmacol, 2023
Reali F, Fochesato A, Kaddi C, Visintainer R, Watson S, Levi M, Dartois V, Azer K, Marchetti L.   +8 more
europepmc   +1 more source

Limitations of Subgroup Safety Analyses for Drug–Drug Interaction Evaluation: Insights from the Talazoparib P‐gp Inhibitor Case

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Impact of concomitant medications (conmeds) on the safety of the investigational agent is often evaluated using subgroup analyses for safety events in patients who received the conmed versus those who did not. Here, we highlight the potential biases and inconclusive results that can arise from such analyses, using talazoparib and P ...
Diane Wang, Charvi Nanavati, Derek Z. Yang, Liza DeAnnuntis, Mohamed Elmeliegy   +4 more
wiley   +1 more source

Integrated PBPK modelling for PFOA exposure and risk assessment

Environmental Research
Per- and polyfluoroalkyl substances (PFASs) pose significant public health concerns due to their environmental persistence, bioaccumulation, and ubiquitous presence in human biomonitoring (HBM) data, despite regulatory restrictions. This study establishes a deterministic pharmacokinetic model for perfluorooctanoic acid (PFOA), enabling the estimation ...
Achilleas Karakoltzidis, Spyros P. Karakitsios, Catherine Gabriel, Dimosthenis Α. Sarigiannis   +3 more
openaire   +2 more sources

Contaminants of emerging concern in agricultural soils: Current understanding, overlooked issues, and future priorities

PLANTS, PEOPLE, PLANET, Volume 8, Issue 3, Page 792-810, May 2026.
Contaminants of emerging concern (CECs) in agriculture represent a growing global challenge for food safety and public health. In this review, we synthesized evidence on how substances such as pharmaceuticals, microplastics, and per‐ and polyfluoroalkyl substances (PFAS) enter soils, accumulate in crops, and affect ecological and human health. We found
Laura J. Carter, Evyatar Ben Mordechay, Benny Chefetz, Zeyou Chen, Xinyi Cui, Jay Gan, Hui Li, Audrey Moores, Xiaoyu Gao   +8 more
wiley   +1 more source

Machine Learning Meets Pharmacokinetics: A Comparative Analysis of Predictive Models for Plasma Concentration‐Time Profiles

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 5, May 2026.
ABSTRACT Predicting pharmacokinetic (PK) profiles from molecular structures represents a significant advancement in pharmaceutical research with substantial implications for expediting drug discovery processes. We evaluated five approaches to systematically compare five distinct methodological frameworks for predicting rat plasma concentration‐time ...
Felix Jost, Clemens Giegerich, Christoph Grebner, Hans Matter, Henrik Cordes   +4 more
wiley   +1 more source

A physiologically based pharmacokinetic/pharmacodynamic model to determine dosage regimens and withdrawal intervals of aditoprim against Streptococcus suis

Frontiers in Pharmacology
Introduction: Streptococcus suis (S. suis) is a zoonotic pathogen threatening public health. Aditoprim (ADP), a novel veterinary medicine, exhibits an antibacterial effect against S. suis.
Kun Mi, Kun Mi, Lei Sun, Lei Sun, Lan Zhang, Lan Zhang, Aoran Tang, Aoran Tang, Xiaoyuan Tian, Xiaoyuan Tian, Yixuan Hou, Yixuan Hou, Lingling Sun, Lingli Huang, Lingli Huang, Lingli Huang   +15 more
doaj   +1 more source

The First Physiologically Based Pharmacokinetic (PBPK) Model for an Oral Vaccine Using Alpha-Tocopherol as an Adjuvant. [PDF]

Pharmaceutics, 2023
Saldanha L, Vale N.
europepmc   +1 more source

Midazolam Dosing During CRRT: A Combined Ex Vivo and Physiologically‐Based Pharmacokinetic Approach

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 5, May 2026.
ABSTRACT Children supported with continuous renal replacement therapy have high mortality rates ranging from 30% to 70%. The cause of this high mortality is multifactorial and includes ineffective drug dosing and altered drug pharmacokinetics. Changes in drug exposure can result from (1) underlying disease; and (2) direct drug interaction and/or ...
Autumn M. McKnite, Abdullah Hamadeh, J. Porter Hunt, Danielle J. Green, Carina Imburgia, Aviva Whelan, Rachel Hudson, Andrew Chevalier, Cheryl L. Mathis, Michelle J. Yang, Jamie P. Dwyer, Andrea Edginton, Kevin M. Watt   +12 more
wiley   +1 more source